Development of factor VIII inhibitors in two patients with moderate haemophilia A

Haemophilia

Volumn 19, Issue 1, 2013, Pages

  Paschal, R D ^a   Meeks, S L ^b   Neff, A T ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ABDOMINAL PAIN; ADULT; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; HEMOPHILIA A; HEPATITIS C; HUMAN; HYDRONEPHROSIS; HYPOVOLEMIC SHOCK; LETTER; MALE; MISSENSE MUTATION; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; PROTHROMBIN TIME;

BLOOD COAGULATION FACTOR INHIBITORS; COAGULANTS; FACTOR VII; FACTOR VIII; HEMOPHILIA A; HUMANS; ISOANTIBODIES; MALE; MIDDLE AGED; MUTATION, MISSENSE; POSTOPERATIVE HEMORRHAGE; YOUNG ADULT;

EID: 84870992847     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12057     Document Type: Letter

References (10)

1. Saenko EL, Ananyeva NM, Tuddenham EG, Kemball-Cook G. Factor VIII - novel insights into form and function. Br J Haematol 2002; 119: 323-31.
2. White GC 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
3. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
4. Prescott R, Nakai H, Saenko EL et al. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups. Blood 1997; 89: 3663-71.
5. Healey JF, Parker ET, Barrow RT, Langley TJ, Church WR, Lollar P. The humoral response to human factor VIII in hemophilia A mice. J Thromb Haemost 2007; 5: 512-9.
6. Eckhardt CL, Menke LA, van Ommen CH et al. Intensive peri-operative use of factor VIII and the Arg593->Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A. J Thromb Haemost 2009; 7: 930-7.
7. Hay CR, Ludlam CA, Colvin BT et al. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost 1998; 79: 762-6.
8. Kempton CL, Soucie JM, Miller CH et al. In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study. J Thromb Haemost 2010; 8: 2224-31.
9. Roelse JC, De Laaf RT, Timmermans SM, Peters M, Van Mourik JA, Voorberg J. Intracellular accumulation of factor VIII induced by missense mutations Arg593->Cys and Asn618->Ser explains cross-reacting material-reduced haemophilia A. Br J Haematol 2000; 108: 241-6.
10. Summers RJ, Meeks SL, Healey JF et al. Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional protein. Blood 2011; 117: 3190-8.